The stock's rise snapped a four-day losing streak.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And ...

Vertex Pharmaceuticals (NASDAQ ... This event is seen as a potential catalyst for the stock, with success potentially opening up a large market opportunity in chronic pain management.

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...

Vertex Pharmaceuticals Incorporated (NASDAQ ... With a beta of 0.41, the stock shows relatively low volatility compared to the market, while trading at an EV/EBITDA multiple of 23.85x, reflecting ...